• Merck Animal Health Ventures-backed Merck Animal Health signed a definitive agreement to acquire poultry biodevice developer TARGAN for an undisclosed price.
• Closing is expected in Q3 2026, subject to customary closing conditions.
• The deal adds WingScan, an automated chick gender identification and sorting system designed to process up to 160,000 chicks per hour.
• TARGAN also brings high-speed ocular spray technology used to administer vaccines to day-old chicks.
• Merck Animal Health has invested in TARGAN since 2017 and has been one of its largest shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Animal Health Ventures published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.